Cite
Neoadjuvant chemotherapy for high-grade serous ovarian cancer: radiologic–pathologic correlation of response assessment and predictors of progression.
MLA
Roseland, Molly E., et al. “Neoadjuvant Chemotherapy for High-Grade Serous Ovarian Cancer: Radiologic–pathologic Correlation of Response Assessment and Predictors of Progression.” Abdominal Radiology, vol. 49, no. 6, June 2024, pp. 2040–48. EBSCOhost, https://doi.org/10.1007/s00261-024-04215-w.
APA
Roseland, M. E., Ma, T., Shampain, K. L., Stein, E. B., Wasnik, A. P., Curci, N. E., Sciallis, A. P., Uppal, S., Johnson, T. D., & Maturen, K. E. (2024). Neoadjuvant chemotherapy for high-grade serous ovarian cancer: radiologic–pathologic correlation of response assessment and predictors of progression. Abdominal Radiology, 49(6), 2040–2048. https://doi.org/10.1007/s00261-024-04215-w
Chicago
Roseland, Molly E., Tianwen Ma, Kimberly L. Shampain, Erica B. Stein, Ashish P. Wasnik, Nicole E. Curci, Andrew P. Sciallis, Shitanshu Uppal, Timothy D. Johnson, and Katherine E. Maturen. 2024. “Neoadjuvant Chemotherapy for High-Grade Serous Ovarian Cancer: Radiologic–pathologic Correlation of Response Assessment and Predictors of Progression.” Abdominal Radiology 49 (6): 2040–48. doi:10.1007/s00261-024-04215-w.